RT Journal Article
SR Electronic
T1 Risk Factors Prediction, Clinical Outcomes and Mortality of COVID-19 Patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.07.20148569
DO 10.1101/2020.07.07.20148569
A1 Alizadehsani, Roohallah
A1 Sani, Zahra Alizadeh
A1 Behjati, Mohaddeseh
A1 Roshanzamir, Zahra
A1 Hussain, Sadiq
A1 Abedini, Niloofar
A1 Hasanzadeh, Fereshteh
A1 Khosravi, Abbas
A1 Shoeibi, Afshin
A1 Roshanzamir, Mohamad
A1 Moradnejad, Pardis
A1 Nahavandi, Saeid
A1 Khozeimeh, Fahime
A1 Zare, Assef
A1 Panahiazar, Maryam
A1 Acharya, U. Rajendra
A1 Islam, Sheikh Mohammed Shariful
YR 2020
UL http://medrxiv.org/content/early/2020/07/09/2020.07.07.20148569.abstract
AB Background Preventing communicable diseases requires understanding the spread, epidemiology, clinical features, progression, and prognosis of the disease. Early identification of risk factors and clinical outcomes might help to identify critically ill patients, provide proper treatment and prevent mortality.Methods We conducted a prospective study in patients with flu-like symptoms referred to the imaging department of a tertiary hospital in IRAN between 3 March 2020 and 8 April 2020. Patients with COVID- 19 were followed up to check their health condition after two months. The categorical data between groups were analyzed by Fisher’s exact test and continuous data by Wilcoxon Rank-Sum Test.Findings 319 patients (mean age 45.48±18.50 years, 177 women) were enrolled. Fever, dyspnea, weakness, shivering, C-reactive protein (CRP), fatigue, dry cough, anorexia, anosmia, ageusia, dizziness, sweating and age were the most important symptoms of COVID-19 infection. Traveling in past three months, asthma, taking corticosteroids, liver disease, rheumatological disease, cough with sputum, eczema, conjunctivitis, tobacco use, and chest pain did not have any relationship with COVID-19.Research in contextEvidence before this studyEvidence before this study We searched Google scholar, PUBMED and Scopus for articles that investigated the recent epidemic of COVID-19, especially those that investigate effective risk factors. We found that there is not enough research in this field, especially the risk factor that is effective in finding the rate of mortality of this disease.Added value of this studyAdded value of this study We determined some of the most important effective risk factors on prediction, clinical outcome and mortality rate of COVID-19 infection. To the best of our knowledge, some of these risk factors are investigated in this work for the first time. Our findings could provide good insight into the early prediction of the disease, its clinical outcomes, and suggest a cost-effective method for mortality prediction.Implication of all the available evidenceImplication of all the available evidence COVID-19 can transmit human-to-human and lead to severe symptoms and high mortality. Early prediction of this disease and the risk of mortality can help the physicians to better manage this worldwide health problem.Interpretation Finding clinical symptoms for early diagnosis of COVID-19 is a critical part of prevention. These symptoms can help in the assessment of disease progression. To the best of our knowledge, some of the effective features on the mortality due to COVID-19 are investigated for the first time in this research.Funding NoneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementFunding: NoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Omid Hospital Ethics Committee.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are private.